The CASCADE Project

Sponsor
The Christie NHS Foundation Trust (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06117592
Collaborator
(none)
1,400
3.6

Study Details

Study Description

Brief Summary

People with cancer, treated for cancer, or have been recently treated for cancer are at a higher risk of becoming rapidly unwell. This is referred to as an oncological emergency and can be life-threatening.

The investigators want to see if a new, standardised assessment of acute oncology knowledge and skills of all health care staff (The Acute Oncology Passport) following education and training, has an effect on the diagnosis and treatment of two relatively-common oncological emergencies: sepsis and MSCC? Sepsis is blood poisoning, which causes serious injuries if it is not diagnosed and treated as an emergency and may result in death if not treated quickly enough. MSCC is metastatic spinal cord compression, where the cancer presses on the spinal cord and can cause permanent paralysis. The investigators have chosen these two conditions, not only because of how serious and relatively common they are for people living with cancer, but also because all NHS Trusts in the UK routinely collect and report standardised data about patients who are admitted with suspected sepsis or MSCC.

The investigators plan to compare data that is routinely collected about the diagnosis and treatment of patients with suspected sepsis and MSCC before and after education, training and assessment of staff about acute oncology. The investigators will conduct 'secondary analysis' on the data, as it was originally collected for another purpose. The routinely data collected at five hospital Trusts across the UK from 1st April 2023 to 30th June 2023 and 1st October to 31st December 2023 will be included in this study.

This research is part of a larger UK-wide project, funded until March 2024 by NHS England Workforce, Training and Education Directorate. If acute oncology education, training and assessment of staff is shown to make a difference to patient diagnosis and treatment, the Acute Oncology Passports will be rolled-out nationally.

Condition or Disease Intervention/Treatment Phase
  • Other: Education, training and assessment intervention

Study Design

Study Type:
Observational
Anticipated Enrollment :
1400 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Co-design of Acute Oncology Standardised Assessment Documents and Their Evaluation
Anticipated Study Start Date :
Dec 11, 2023
Anticipated Primary Completion Date :
Mar 29, 2024
Anticipated Study Completion Date :
Mar 29, 2024

Arms and Interventions

Arm Intervention/Treatment
Pre-Intervention

Retrospective data collection for pre-education intervention period: 1st April 2023- 1st June 2023

Other: Education, training and assessment intervention
Staff competence assessment documents for acute oncology knowledge and skills

Post-Intervention

Retrospective data collection for post-education intervention period: 1st October 2023- 31st December 2023

Other: Education, training and assessment intervention
Staff competence assessment documents for acute oncology knowledge and skills

Outcome Measures

Primary Outcome Measures

  1. Acute Oncology Key Performance Indicators (KPIs) [1st April 2023- 31st December 2023]

    These are routinely collected metrics by acute oncology teams for patients presenting with suspected neutropenic sepsis or metastatic spinal cord compression.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All patient KPI's of interest that occur in the study time frame will be collected.
Exclusion Criteria:
  • KPI data collected from people under the age of 18 KPI data other than items stated in this application, i.e. data that is not reporting neutropenic sepsis nor MSCC outcomes

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • The Christie NHS Foundation Trust

Investigators

  • Study Director: Clare Griffin, PhD, The Christie NHS Foundation Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
The Christie NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT06117592
Other Study ID Numbers:
  • cftsp227
First Posted:
Nov 7, 2023
Last Update Posted:
Nov 9, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Nov 9, 2023